Ganoderma Lucidum G2 Strain for High-Yield Mycelia Fermentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Wild Ganoderma Lucidum strains are unsuitable for large-scale production of Ganoderma products due to defects in industrial production, failing to meet the requirements for high-yield and pharmaceutical ingredient content.
Innovation Solution
A Ganoderma Lucidum strain named Ganoderma Lucidum G2 is developed through mutagenizing and breeding, involving protoplast isolation, UV radiation, NaN3 chemical mutagenesis, and transient heating, optimized for large-scale liquid fermentation, resulting in a strain suitable for efficient production of mycelia with enhanced pharmaceutical ingredient content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild Ganoderma Lucidum strains are used for propagation, then the strain can be obtained from nature, but the productivity and pharmaceutical ingredient content are insufficient for large-scale production
Solution Approach 1:
The patent applies parameter changes by subjecting wild Ganoderma Lucidum strains to multiple mutagenic treatments (UV radiation, chemical mutagens, physical stress) that alter genetic parameters, resulting in strain G2 with dramatically improved mycelia production efficiency and stable pharmaceutical ingredient content suitable for large-scale liquid fermentation
Solution Approach 2:
The patent replaces traditional mechanical propagation methods with a systematic mutagenesis and selection process, using controlled genetic modification techniques to develop strains with optimized production characteristics rather than relying on natural propagation
2Ease of manufacture
If wild Ganoderma Lucidum strains are used, then no complex breeding process is needed, but the strain cannot meet requirements of large-scale production
Solution Approach 1:
The patent applies preliminary action by conducting extensive mutagenesis and screening processes in advance to pre-develop strain G2 with optimized characteristics for large-scale liquid fermentation, so that when production is needed, a ready-to-use high-performance strain is already available
Solution Approach 2:
Through systematic genetic parameter modification using multiple mutagenic agents and selection criteria, the patent transforms wild strains into the optimized G2 strain capable of meeting large-scale production requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Ganoderma Lucidum G2 strain achieves 80-120 times higher mycelia production and higher pharmaceutical ingredient content compared to wild-type strains, enabling the production of stable oral solutions or beverages with improved healthcare benefits.
Implementation Method 1
subjecting the wild-type naïve Ganoderma mycelia from step (2) to a combinatory mutagenizing and breeding process of UV radiation
Implementation Method 2
NaN3 chemical mutagenesis
Implementation Method 3
transient heating in sterile water at 80° C. ̃90° C.
Implementation Method 4
subjecting pileus and stipe of non-lignified wild Ganoderma fruiting body to protoplast isolation
Implementation Method 5
large-scale liquid fermentation culture
Data Source
AI summary
Disclosed is a Ganoderma Lucidum strain suitable for large-scale liquid fermentation, named as Ganoderma Lucidum G2, deposited with China General Microbiological Culture Collection Center under the accession number CGMCC No. 3982 on Jul. 20, 2010, and a method of mutation breeding the same and use of the strain. The Ganoderma Lucidum strain which belongs to Ganodermataceae, genus Ganoderma, species red Ganoderma Lucidum is obtained by artificial mutagenizing and breeding. The production of mycelia using the Ganoderma Lucidum strain G2 is 80˜120 times higher as compared with the production of mycelia using wild-type naïve Ganoderma Lucidum strain. The mycelia produced using the Ganoderma Lucidum strain G2 have higher contents of main pharmaceutical ingredients. The Ganoderma Lucidum strain suitable for large-scale liquid fermentation can be used for manufacturing oral solution or beverage comprising Ganoderma mycelia or extracts of Ganoderma mycelia as main active ingredient.